Temozolomide (NSC 362856), DNA Alkylator

Temozolomide (NSC 362856) is an oral active DNA alkylating agent that crosses the blood-brain barrier. Temozolomide is also a proautophagic and proapoptotic agent. Temozolomide is effective against tumor cells that are characterized by low levels of O6-alkylguanine DNA alkyltransferase (OGAT) and a functional mismatch repair system. Temozolomide has antitumor and antiangiogenic effects. - Mechanism of Action & Protocol.

Temozolomide-d3, Stable Isotope

Evaluation of the exposure equivalence of oral versus intravenous temozolomide

DNA Damage/DNA Repair - BioCrick

Variant allele frequency enrichment analysis in vitro reveals sonic hedgehog pathway to impede sustained temozolomide response in GBM

Molecules, Free Full-Text

Temozolomide nano enabled medicine: promises made by the nanocarriers in glioblastoma therapy - ScienceDirect

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

Current and future developments in the use of temozolomide for the treatment of brain tumours - The Lancet Oncology

PDF) Phase I study of temozolomide in paediatric patients with advanced cancer

Selleck Chemical LLC Temozolomide 100mg 85622-93-1 CCRG81045, NSC 362856,TMZ

Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide in: Journal of Neurosurgery Volume 99 Issue 6 (2003) Journals

T1178-50mg Temozolomide [85622-93-1] Hexabiogen

Temozolomide resistance in glioblastoma multiforme. - Abstract - Europe PMC